In our current landscape, this announcement is likely an update...

In our current landscape, this announcement is likely an update to shareholders on a new regulatory approval pathway we have applied for.

The unknown is how this relates to Sanofi. The timing of the announcement is aligns to the expiry of Sanofi's option to continue with our collaboration effort. Perhaps management thought it would be best to amend our FDA approval submission to include the direct to consumer application of our tech.

Expect the unexpected